Methylmalonyl-CoA

Clinical Development Update from Portfolio Company LogicBio

Retrieved on: 
Monday, May 9, 2022
Capsid, Generides, Homologous recombination, IND, Nasdaq, SUNRISE, EMA, Mouse, European Medicines Agency, Biotechnology, Genome, AAV, Food, Methylmalonic acidemia, Safety, Time, Patient, Review, Survival, Methylmalonyl-CoA, FDA, Letter, Hepatocyte, Cancer, Industry, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, DNA, Lifting, Tissue, Thrombotic microangiopathy, Methylmalonyl-CoA mutase, List of life sciences, Liver, TMA, Time-invariant system, Growth, Risk, Therapy, Pharmaceutical industry, Vaccine, MMA

As a listed company, we are able to bring this exciting growth phase of our industry to a broader range of investors.

Key Points: 
  • As a listed company, we are able to bring this exciting growth phase of our industry to a broader range of investors.
  • In its letter, the FDA acknowledged that the company satisfactorily addressed all clinical hold issues.
  • In connection with the lifting of the clinical hold, LogicBio amended the SUNRISE protocol in a manner that reflected its dialogue with the FDA.
  • LogicBio Therapeutics is a clinical-stage genetic medicine company pioneering genome editing and gene delivery platforms to address rare and serious diseases from infancy through adulthood.

LogicBio Therapeutics Provides Business Updates

Retrieved on: 
Wednesday, December 22, 2021
Hepatocyte, Technology, Seizure, Disease, Tissue, Acquisition, Enzyme, COVID-19, Leadership, Generides, Brain, Clinical trial, Methylmalonyl-CoA, DNA, Patent, Methylmalonic acidemia, Risk, Patient, Vomiting, Genetic disorder, Bleeding, Board, Dartmouth, Acetone, Cancer, Nosebleed, Diarrhea, Hope, First Ever, Lethargy, AAV, Goal, Nervous system, Life, Genome, Time, Safety, SAE, Business, Shuttle Mission Simulator, Therapy, Brown University, Capsid, Mutation, Mouse, Profile, Homologous recombination, Tuck School of Business, Growth, FAH, Fats, Protein, Saavi, Board of directors, Survival, Jaundice, ESGCT, EMA, Liver, Lists of diseases, Bya, Research, FDA, Methylmalonyl-CoA mutase, Pharmaceutical industry, Vaccine, SUNRISE, MMA

LEXINGTON, Mass., Dec. 22, 2021 /PRNewswire/ --LogicBio Therapeutics, Inc.(Nasdaq: LOGC), a clinical-stage genetic medicine company, today provided updates around its SUNRISE Phase 1/2 clinical trial and development pipeline, and announced the appointment of Susan R. Kahn to its Board of Directors.

Key Points: 
  • LEXINGTON, Mass., Dec. 22, 2021 /PRNewswire/ --LogicBio Therapeutics, Inc.(Nasdaq: LOGC), a clinical-stage genetic medicine company, today provided updates around its SUNRISE Phase 1/2 clinical trial and development pipeline, and announced the appointment of Susan R. Kahn to its Board of Directors.
  • In accordance with its previously announced guidance, LogicBio alsoannounced the nomination of a new development candidate, LB-401, for the treatment of hereditary tyrosinemia type 1 (HT1).
  • in applied mathematics-economics from Brown University and an M.B.A. from the Tuck School of Business at Dartmouth.
  • "I am excited to join the LogicBio Board at what I believe is a pivotal time for the company," said Ms. Kahn.

LogicBio Therapeutics Announces Early Clinical Trial Results Demonstrating First-Ever In Vivo Genome Editing in Children

Retrieved on: 
Monday, October 18, 2021
EMA, List of life sciences, AAV, Fats, Generides, Data monitoring committee, Genome, Industry, Liver, Time, Nasdaq, Methylmalonyl-CoA, Risk, Cancer, Growth, Mouse, Lethargy, Trial of the century, Capsid, European Medicines Agency, Protein, Tissue, Saavi, Methylmalonyl-CoA mutase, Brain, Mutation, FDA, Disease, DNA, Clinical trial, Patient, Survival, Food, Methylmalonic acidemia, DSMB, Seizure, Company, CRISPR, Drug development, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Vomiting, SUNRISE, MD, Safety, Hepatocyte, Therapy, Homologous recombination, Lists of diseases, Pharmaceutical industry, Vaccine

www.arixbioscience.com

Key Points: 
  • www.arixbioscience.com
    - Based on safety data from first two patients, independent Data Safety Monitoring Board recommended continuation of trial, enabling enrollment of children as young as six months and dose escalation
    LEXINGTON, Mass., Oct. 18, 2021 -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a clinical-stage genetic medicine company, today announced clinical trial results demonstrating the first-ever in vivo genome editing in children.
  • The SUNRISE trial is evaluating the safety, tolerability and preliminary efficacy of LB-001, the company's investigational, single-administration genome editing therapy, in pediatric patients with methylmalonic acidemia (MMA).
  • These results follow a recommendation from the independent Data Safety Monitoring Board (DSMB) overseeing the SUNRISE trial to continue the study without modification.
  • We look forward to continuing to progress the clinical study to better understand the biochemical and clinical effect of this genome editing therapy."